Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Belatacept (Primary) ; Antithymocyte globulin; Everolimus; Methylprednisolone; Mycophenolate mofetil; Prednisone
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 24 Sep 2019 Status changed from active, no longer recruiting to completed.
- 05 Dec 2018 Planned End Date changed from 31 Jul 2019 to 6 Nov 2019.
- 05 Dec 2018 Planned primary completion date changed from 31 Jan 2019 to 4 Oct 2019.